4Chen J, Normand SL, Wang Y, et ah National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008[J]. JAMA. 2011, 306 (15) : 1669-1678.
5Krum H, Teerlink JR. Medical therapy for chronic heart failure[J]. Lancet, 2011, 378(9792): 713-721.
6Konstam MA, Kramer DG, Patel AR, et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment[J]. JACC Cardiovasc Imaging. 2011,4(1) :98-108.
7Moriarty TF. The law of Laplace. Its limitations as a relation for diastolic pressure, volume, or wail stress of the left ventricle[J]. Circ Res, 1980,46(3):321-331.
8Torrent-Guasp F, Ballester M, Buckberg GD, et al. Spatial orientation of the ventricular muscle band: physiologic contribution and surgical implications [ J ]. J Thorac Cardiovasc Surg, 2001,122(2) : 389-392.
9Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications [J]. Circulation, 2002,106(18) :2351-2357.
10Dor V, Saab M, Coste P, et aL Left ventricular aneurysm: a new surgical approach[J]. J Thorac Cardiovasc Surg, 1989, 37(1):11- 19.
二级参考文献58
1叶任高 主编.内科学:第5版[M].北京:人民卫生出版社,2001.824.
2Otasevic P, Sagic D, Antonic Z, et al. First-in-man implantation of left ventricular partitioning device in a patient with chronic heart failure: twelve-month follow-up. J Card Fail, 2007, 13 : 517-520.
3Mazzaferri EL Jr, Gradinac S, Sagie D, et al. Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Yentricular RestorAtion in Chronic Heart failure PaTiEnts Trial. Am Heart J, 2012, 163:812-820.
4Costa MA,Pencina M, Nikolic S, et al. The PARACHUTE 1V trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J, 2013, 165:531-536.
5Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure[J]. Eur J Heart Fail, 2007, 9(11): 1120-1127.
6van Esch JH, Mohzer E, van Veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats [J]. J Hypertens, 2010, 28 ( 10 ) : 2145 -2155.
7McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure[J]. Circulation Heart Fail, 2008. 1(1): 17-24.
8Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction[J]. Eur Heart J, 2011, 32(10) : 1227-1234.
9Pitt B, Latini R, Maggioni AP, et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocortieoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study[J]. Eur J Heart Fail, 2011, 13(7) : 755-764.
10Azizi M, Frank M, Steichen O, et al. Advantages and limitations of renin inhibition with aliskiren [ C]. Ann Pharma Fr,2011, 69(3) : 142- 150.
